Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

101

Full text

Free full text

Publication Types

Journal Article

103

Review

Research Support, Non-U.S. Gov't

Randomized Controlled Trial

Comparative Study

Multicenter Study

Meta-Analysis

Systematic Review

Clinical Trial

Clinical Trial, Phase III

Clinical Trial, Phase II

Research Support, N.I.H., Extramural

Comment

Clinical Trial, Phase I

Research Support, U.S. Gov't, Non-P.H.S.

Letter

Research Support, U.S. Gov't, P.H.S.

Evaluation Study

Network Meta-Analysis

Clinical Trial Protocol

Editorial

Publication Year

From

Quick links

Individual year

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2001

2000

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Benzylamines""[mesh_terms]

105 Results

Searching titles within these results

Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions.

Milind Y Desai, Tiffany Dong, Ben Alencherry, Susan Ospina

Drug design, development and therapy 2023;17():1097-1106

Free Full Text

Abstract

An evaluation of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults.

Tiffany Dong, Steven Nissen, Susan Ospina, Milind Y Desai

Expert review of cardiovascular therapy 2023;21(1):5-13

Full Text

Abstract

2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOME): A Harmful Hallucinogen Review.

Katarzyna Kamińska, Paweł Świt, Kamilla Malek

Journal of analytical toxicology 2021;44(9):947-956

Full Text

Abstract

Effects of mavacamten on Ca sensitivity of contraction as sarcomere length varied in human myocardium.

Bertrand C W Tanner, Kenneth S Campbell, Maya A Guglin, Marissa Watanabe, Yemeserach Bishaw, Peter O Awinda

British journal of pharmacology 2021;177(24):5609-5621

Free Full Text

Abstract

Mavacamten-A Targeted Therapy for Hypertrophic Cardiomyopathy.

Ashley Schenk, Nathan Fields

Journal of cardiovascular pharmacology 2023;81(5):317-326

Full Text

Abstract

The role of ximelagatran in the treatment of venous thromboembolism.

Sam Schulman

Pathophysiology of haemostasis and thrombosis 2005;34 Suppl 1():18-24

Full Text

Abstract

Pharmacokinetics and pharmacodynamics of ximelagatran.

Michael Wolzt, Troy S Sarich, Ulf G Eriksson

Seminars in vascular medicine 2005;5(3):245-53

Full Text

Abstract

Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy.

Perry M Elliott, Sara Saberi, Sheila M Hegde, Neal K Lakdawala, Jonathan Myers, Amy J Sehnert, Jay M Edelberg, Wanying Li, Iacopo Olivotto, Daniel Jacoby, Matthew T Wheeler

European journal of heart failure 2023;25(2):260-270

Free Full Text

Abstract

Ximelagatran for stroke prevention in atrial fibrillation.

Gregory Y H Lip, Christopher J Boos

Expert review of cardiovascular therapy 2006;3(4):551-63

Full Text

Abstract

Current status of safinamide for the drug portfolio of Parkinson's disease therapy.

Thomas Müller

Expert review of neurotherapeutics 2014;13(9):969-77

Full Text

Abstract

Mavacamten, a First-in-Class Cardiac Myosin Inhibitor for Obstructive Hypertrophic Cardiomyopathy.

Joseph D Dalo, Nissen D Weisman, C Michael White

The Annals of pharmacotherapy 2023;57(4):489-502

Full Text

Abstract

Disposition and metabolism of safinamide, a novel drug for Parkinson's disease, in healthy male volunteers.

Chiara Leuratti, Marco Sardina, Paolo Ventura, Alessandro Assandri, Markus Müller, Martin Brunner

Pharmacology 2014;92(3-4):207-16

Full Text

Abstract

Ximelagatran: a new oral anticoagulant.

Charles W Francis

Best practice & research. Clinical haematology 2005;17(1):139-52

Full Text

Abstract

Preventing stroke in atrial fibrillation: the SPORTIF programme.

Gregory Y H Lip

Pathophysiology of haemostasis and thrombosis 2005;34 Suppl 1():25-30

Full Text

Abstract

Drug insight: an overview of current anticoagulation therapy after heart valve replacement.

Detlef Hering, Cornelia Piper, Dieter Horstkotte

Nature clinical practice. Cardiovascular medicine 2005;2(8):415-22

Full Text

Abstract

Results: 1 – 15 / 105

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Benzylamines""[mesh_terms]

Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions.

An evaluation of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults.

2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOME): A Harmful Hallucinogen Review.

Effects of mavacamten on Ca sensitivity of contraction as sarcomere length varied in human myocardium.

Mavacamten-A Targeted Therapy for Hypertrophic Cardiomyopathy.

The role of ximelagatran in the treatment of venous thromboembolism.

Pharmacokinetics and pharmacodynamics of ximelagatran.

Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy.

Ximelagatran for stroke prevention in atrial fibrillation.

Current status of safinamide for the drug portfolio of Parkinson's disease therapy.

Mavacamten, a First-in-Class Cardiac Myosin Inhibitor for Obstructive Hypertrophic Cardiomyopathy.

Disposition and metabolism of safinamide, a novel drug for Parkinson's disease, in healthy male volunteers.

Ximelagatran: a new oral anticoagulant.

Preventing stroke in atrial fibrillation: the SPORTIF programme.

Drug insight: an overview of current anticoagulation therapy after heart valve replacement.

Results for
""Benzylamines""[mesh_terms]